Review
Open access
Jul 2026
O-GlcNAcylation at the tumor–immune interface: a metabolic post-translational code driving immune evasion and therapy resistance in cancer
This framework highlights opportunities for developing next-generation low-toxicity therapeutics, including substrate-selective inhibitors and PROTAC degraders, in rational combinations with chemotherapy, radiotherapy, and immunotherapy.
Shan-Shan Liu, P. Zhan, Wenjie Tian et al.
· Frontiers in Immunology · 0 citations